Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
51 studies found for:    Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate OR Stribild[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: NNRTI;   Drug: FTC/TDF;   Drug: Stribild
2 Active, not recruiting Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: EVG/COBI/FTC/TDF
3 Completed
Has Results
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: Stribild
4 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: PI;   Drug: RTV;   Drug: FTC/TDF;   Drug: Stribild
5 Recruiting Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals
Condition: HIV
Interventions: Drug: Stribild;   Drug: Genvoya
6 Active, not recruiting
Has Results
Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: E/C/F/TDF Placebo;   Drug: RTV Placebo;   Drug: ATV Placebo;   Drug: FTC/TDF Placebo;   Drug: E/C/F/TAF
7 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
8 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
9 Active, not recruiting
Has Results
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: E/C/F/TAF Placebo;   Drug: E/C/F/TAF;   Drug: E/C/F/TDF Placebo
10 Recruiting Sleep and Cognition After Atripla to Stribild Switch
Condition: HIV
Interventions: Drug: Stribild;   Drug: Atripla
11 Recruiting Safety and Efficacy of Switching to a FDC of GS-9883/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
Condition: HIV-1 Infection
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: ATV;   Drug: RTV;   Drug: FTC/TDF;   Drug: GS-9883/F/TAF
12 Recruiting HIV Non-Occupational Post-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus
Intervention: Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
13 Recruiting Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
Condition: HIV-1 Infection
Interventions: Drug: E/C/F/TAF;   Drug: TDF;   Drug: FTC;   Drug: FTC/TDF;   Drug: 3TC;   Drug: Third agent
14 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla;   Drug: Stribild Placebo;   Drug: Atripla Placebo
15 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: Stribild Placebo;   Drug: ATV Placebo;   Drug: RTV Placebo;   Drug: FTC/TDF Placebo
16 Completed
Has Results
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla
17 Active, not recruiting An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Condition: HIV-2 Infection
Intervention: Drug: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
18 Unknown  Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
Condition: HIV
Interventions: Drug: Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra);   Drug: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
19 Active, not recruiting
Has Results
Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: EFV/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI
20 Completed Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
Conditions: HIV;   AIDS;   Sleep Disorders
Intervention: Drug: elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years